Analysis of Diffusion Tensor Imaging Data From the UK Biobank Confirms Dosage Effect of 15q11.2 Copy Number Variation on White Matter and Shows Association With Cognition

Ana I. Silva, George Kirov, Kimberley M. Kendall, Mathew Bracher-Smith, Lawrence S. Wilkinson, Jeremy Hall, Magnus O. Ulfarsson, G. Bragi Walters, Hreinn Stefansson, Kari Stefansson, David E.J. Linden, and Xavier Caseras

ABSTRACT

BACKGROUND: Copy number variations at the 15q11.2 BP1-BP2 locus are present in 0.5%–1.0% of the population, and the deletion is associated with several neurodevelopmental disorders. Previously, we showed a reciprocal effect of 15q11.2 copy number variation on fractional anisotropy, with widespread increases in deletion carriers. We aim to expand these findings using a larger sample of participants (N = 29,166) and higher resolution imaging and by examining the implications for cognitive performance.

METHODS: Diffusion tensor imaging measures from participants with no neurological or psychiatric diagnoses were obtained from the UK Biobank database. We compared 15q11.2 BP1-BP2 deletion (n = 102) and duplication (n = 113) carriers to a large cohort of control individuals with no neuropsychiatric copy number variants (n = 28,951). Additionally, we assessed how changes in white matter mediated the association between carrier status and cognitive performance.

RESULTS: Deletion carriers showed increases in fractional anisotropy in the internal capsule and cingulum and decreases in the posterior thalamic radiation compared with both duplication carriers and control subjects (who had intermediate values). Compared with control subjects, deletion carriers had lower scores across cognitive tasks, which were partly influenced by white matter. Reduced fractional anisotropy in the posterior thalamic radiation partially contributed to worse cognitive performance in deletion carriers.

CONCLUSIONS: These results, together with our previous findings, provide convergent evidence for an effect of 15q11.2 BP1-BP2 on white matter microstructure, this being more pronounced in deletion carriers. Additionally, changes in white matter were found to partially mediate cognitive ability in deletion carriers, providing a link between white matter changes in 15q11.2 BP1-BP2 carriers and cognitive function.

https://doi.org/10.1016/j.biopsych.2021.02.969

Several copy number variants (CNVs) are associated with neurodevelopmental disorders (NDDs) in genome-wide studies, including intellectual disability, autism spectrum disorder (ASD), epilepsy, and schizophrenia (1–3). Altered white matter is common in many NDDs and has been shown to mediate core cognitive deficits in schizophrenia (4,5). However, whether alterations in white matter microstructure are associated with these CNVs and can explain—at least partly—cognitive deficits in carriers of the risk variants is not yet fully understood.

The chromosome 15q11-13 region contains five breakpoints (BPs) that can give rise to CNVs (6). Deletions and duplications at 15q11.2 BP1-BP2 are the most prevalent in humans, being present in 0.5%–1.0% of the general population (7,8). Deletions are associated with developmental and motor delays (9), as well as increased susceptibility to attention-deficit/hyperactivity disorder, ASD, schizophrenia, epilepsy (1,10), and congenital heart disease (11–13), whereas the pathogenicity of the corresponding duplication is less clear in population samples, where a significant risk for NDDs has not been established (1,3) despite its link to neurodevelopmental phenotypes in clinical samples (14,15). Carriers of the 15q11.2 BP1-BP2 deletion, unaffected by a diagnosed NDD, show lower cognitive function than noncarrier control subjects (11,16), as well as a higher prevalence of dyslexia and dyscalculia (7,17), whereas carriers of the corresponding duplication perform similarly to control subjects on many cognitive tests (16,17).

The 15q11.2 BP1-BP2 interval comprises four genes: NIPA1, NIPA2, CYFIP1, and TUBGCP5 (18). These genes are expressed in the central nervous system and have been individually associated with multiple disorders: NIPA1 with...
autosomal-dominant hereditary spastic paraplegia (19), NIPA2 with childhood absence epilepsy (20), TUBHGCP5 with attention-deficit/hyperactivity disorder and obsessive-compulsive disorder (10), and CYFIP1 with increasing susceptibility to ASD (21) and schizophrenia (22). A recent report investigated protein–protein interactions of the four genes in this region and found that they interact with each other and that their predicted functions encompass crucial biological processes that are important for normal neuronal development, plasticity, and function (23).

Using diffusion tensor imaging (DTI), we have previously shown an association between 15q11.2 BP1-BP2 CNV dosage and altered white matter microstructure in an Icelandic sample (24). We found widespread increases of fractional anisotropy (FA) in deletion carriers relative to duplication carriers, with noncarrier control subjects showing intermediate values, and the largest effects were observed in the posterior limb of the internal capsule. The Icelandic gene pool is less heterogeneous than that of most European populations (25), facilitating the reduction of background noise caused by genetic variation (26) but arguably also raising concerns about the replicability of these findings in more genetically diverse, heterogeneous populations (27).

The aim of this study was to expand our previous findings to a more heterogeneous European population, using a bigger sample and higher resolution imaging, and to further investigate the potential mediation effects of white matter changes on the association between 15q11.2 BP1-BP2 and cognitive performance. To this end, we used a subsample of participants (~29,000) from the UK Biobank for whom DTI-derived measures, along with genetic data, were available. Based on our previous findings, we hypothesized a dose-effect association between 15q11.2 BP1-BP2 carrier status and DTI-based white matter measures, with greater effects in deletion carriers. We also predicted white matter changes to mediate the association between this CNV and cognitive performance in deletion carriers.

**METHODS AND MATERIALS**

**Participants**

A subsample of participants from the UK Biobank (www.ukbiobank.ac.uk) was used in this study. Ethical approval was granted by the North West Multi-Centre Ethics committee, and all subjects provided informed consent to participate in the UK Biobank project. Data were released to Cardiff University after application to the UK Biobank (project ref. 17044).

To avoid potential confounding from population stratification, we only selected participants who self-reported as white British or Irish descent and for whom white British and Irish ancestry was confirmed, using the two first principal components provided by the UK Biobank (28) (Figure S1 in Supplement 1) (73,126 participants removed). Furthermore, to avoid confounding effects of disease, only participants with no personal history—based on self-reported diagnosis from a doctor at any assessment visit or existing hospital records—of neuropsychiatric disorders (i.e., schizophrenia, psychosis, ASD, dementia, or intellectual disability) or medical/neurological conditions that could impact white matter (i.e., alcohol or other substance dependency, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, or other neurodegenerative disorders) were selected (37,176 participants removed). After applying these exclusions, 392,340 participants remained (the number of participants excluded per carrier group and condition is presented in Table S1 in Supplement 2).

**Genotyping, CNV Calling, and CNV Quality Control**

DNA extraction and processing workflow are described at https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/genotyping_sample_workflow.pdf. CNV calling was performed by Kendall et al. (29), and quality control parameters are briefly explained in Supplemental Methods in Supplement 1. Carriers of CNVs at the 15q11.2 BP1-BP2 locus and participants with no neurodevelopmental CNVs (NoCNV) were selected. For the NoCNV group, we selected participants that carried none of the 93 CNVs (Table S2 in Supplement 2) that have previously been associated with NDDs (3,30,31). The 15q11.2 BP1-BP2 interval was manually inspected to confirm that it included the key genes within the region (Table S3 in Supplement 2). We found 1468 15q11.2 BP1-BP2 deletion carriers, 1752 duplication carriers, and 356,257 NoCNV carriers in the remaining sample after exclusions and quality control.

**DTI Data**

We used standard DTI measures made available by the UK Biobank. Imaging protocols can be found in brain magnetic resonance imaging documentation (http://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/brain_mri.pdf). DTI data were acquired using a multishell approach with two b-values (b = 1000 and 2000 s/mm²). For each diffusion-weighted shell, 50 diffusion-encoding directions were acquired. Tensor fitting utilizes b = 1000 s/mm² data, leading to the generation of FA, axial diffusivity (AD), radial diffusivity (RD), and mean diffusivity (MD) maps. DTI maps were used in Tract-Based Spatial Statistics (TBSS) processing, and TBSS-derived measures were computed by averaging the skeletonized images of each DTI map within a set of 48 standard-space tract masks defined by the JHU White Matter Atlas (ICBM-DTI-81) (32).

DTI data were available for 29,978 participants in the UK Biobank; of those, 102 were 15q11.2 BP1-BP2 deletion carriers, 113 were duplication carriers, and 28,951 were NoCNV carriers. Participants were aged between 40 and 70 years, and the numbers of females and males were similar in each group. Demographic information is provided in Table 1.

To avoid the potential effect of extreme values that could have resulted from poor data quality or processing problems, outlier values of FA, AD, RD, and MD, defined as values ± 2.5 SDs from the group mean, were removed from the analyses. Outlier identification was run individually for each white matter tract and within each carrier group. The number of data points excluded per tract and carrier group are presented in Table S4 in Supplement 2. Overall, no carrier group had a significant excess of outlier data points compared with the other groups.

The mean TBSS-derived measures (FA, AD, RD, and MD) from 30 white matter tracts were considered for analyses (Table 2). These included the tracts analyzed in our previous study (24) plus other regions recently highlighted because of their association with psychiatric disorders (33).
Cognitive Data

Participants in the UK Biobank also underwent a series of cognitive tests. We evaluated the performance on seven cognitive tasks that had been performed by at least 10% of the participants: the pairs matching, reaction time, fluid intelligence, digit span, symbol digit substitution, and trail making A and B tasks. Cognitive measures were normally distributed and standardized following a previously published approach (29), detailed in Supplemental Methods in Supplement 1. All cognitive measures were transformed so that lower values represented poorer performance. Table 3 describes the sample sizes used for each task in our neuroimaging sample. Because cognitive data are available for many more participants in the UK Biobank than those with neuroimaging data, we also report an extended analysis considering the full sample in Table S6 in Supplement 2.

Statistical Analyses

Statistical analyses were performed in R V3.6.3 (R Foundation). CNV group effects were examined via analysis of variance, including age, sex, and handedness as covariates. For brain measures, we also included brain size (total gray matter + white matter volumes) as a covariate. Post hoc pairwise comparisons were performed to measure differences between groups (deletion vs. NoCNV, duplication vs. NoCNV, and deletion vs. duplication). We used the Benjamini-Hochberg false discovery rate (p, .05) to account for multiple testing (34), for a total of 360 tests (30 tracts × 4 TBSS-derived measures × 3 group comparisons) in the case of imaging data and a total of 21 tests (7 cognitive test × 3 group comparisons) in the case of cognitive data. The interactions between copy number and age and between copy number and sex were also assessed. We repeated the analyses without excluding participants with neurological/psychiatric conditions (Tables S5 and S6 in Supplement 2).

Cohen’s d effect sizes were calculated for the pairwise comparisons. Adjusted values for each group were used, regressing out the effects of age, sex, handedness, and brain volume using linear regression. Effect sizes across TBSS-
derived measures for each comparison are shown in Figures S2–S4 in Supplement 1. Cohen classified effect sizes as negligible (d < 0.2), small (0.2 < d < 0.5), medium (0.5 < d < 0.8), and large (d > 0.8) (35).

To best examine the concordance between our current findings in the UK Biobank sample and our previous findings in the Icelandic deCODE sample (24), we plotted the effect sizes from both samples using forest plots. To facilitate the comparison, we recalculated the effect sizes from the Icelandic sample using adjusted values for age, sex, and brain volume, and only white matter tracts showing group differences in either study are shown (Figures S5–S7 in Supplement 1).

Mediation analysis was performed to test the hypothesis that 15q11.2 BP1–BP2 CNV effects on cognition are mediated by white matter abnormalities. Tracts showing a significant association between FA and carrier status were considered, as well as cognitive tasks that were significantly affected in carriers when compared with NoCNV carriers. Linear regression was used to look at overall effects of white matter on cognitive tasks (including all deletion and duplication carriers). Mediation analysis was conducted using the mediation package version 4.4.7 in R (http://CRAN.R-project.org/package=mediation), which uses structural equation modeling. We report the proportion of the total effect of copy number on cognitive performance mediated by FA, with p values calculated through quasi-Bayesian approximation (13).

Cognitive Performance in 15q11.2 CNV Carriers

In our neuroimaging sample, deletion carriers showed poorer performance on reaction time, fluid intelligence, symbol substitution, and trail making B tasks, whereas duplication carriers achieved a similar level of performance as NoCNV carriers (Table 3). This was also true when considering all participants with cognitive data (Table S6 in Supplement 2), where deletion carriers showed poorer performance in pairs matching, reaction time, fluid intelligence, digit span, symbol substitution, and trail making B tasks; duplication carriers showed poorer performance only in pairs matching task and no effects on other tasks. No significant CNV × age or CNV × sex interactions were observed for cognitive performance (see Supplemental Findings in Supplement 1 and Tables S8 and S9 in Supplement 2).

RESULTS

Group Differences on TBSS-Derived Measures

15q11.2 BP1–BP2 deletion carriers showed increased FA relative to duplication carriers in ALIC_L, PLIC_L, Cing_HIP_R, and Cing_HIP_L and decreased FA in fornix and PTR_R (see Figure 1 and Table S7 in Supplement 2 for statistics). Deletion carriers also showed increased FA in ALIC_L, PLIC_L, and Cing_HIP_L and decreased FA in PTR_R when compared with NoCNV carriers. Additionally, deletion carriers showed significant decreases in MD in BodyCC and Unc_L and significant decreases in AD in BodyCC and SpleniumCC when compared with NoCNV carriers. 15q11.2 BP1–BP2 duplication carriers showed reduced FA in Cing_CC_R, Cing_HIP_R, and Cing_HIP_L compared with NoCNV carriers. The effect sizes for FA were overall small (Cohen’s d < 0.5) when comparing carriers to noncarriers. Larger effects were found when comparing deletion to duplication carriers, these being of medium size (Cohen’s d > 0.5) for Cing_HIP_R, and Cing_HIP_L (Table S7 in Supplement 2), the latter showing a significant dosage effect with deletion and duplication carriers differing from NoCNV carriers in opposing directions. Diverging bar plots showing effect sizes for all 30 white matter tracts considered are shown in Figures S8–S11 in Supplement 1.

No significant CNV × age and CNV × sex interactions were found after multiple testing correction (see Supplemental Findings in Supplement 1 and Tables S8 and S9 in Supplement 2).

In the UK Biobank imaging sample, we found 4 deletion and 3 duplication carriers who carried an additional damaging CNV. We repeated the analysis removing these participants, which did not alter our results.

Table 3. Effects of 15q11.2 BP1–BP2 Copy Number Variation on Cognitive Performance in UK Biobank Participants for Whom DTI Data Were Available

| Effects | 15q11.2 BP1–BP2 CNVs | Deletion vs NoCNV | Duplication vs NoCNV | Dosage |
|---------|---------------------|------------------|---------------------|--------|
|         | Deletion, n | NoCNV, n | Duplication, n | Cohen’s d (SE) | p Value | P<sub>FDR</sub> | Cohen’s d (SE) | p Value | P<sub>FDR</sub> | F Statistic | p Value |
| Pairs Matching | 102 | 28,599 | 112 | −0.04 (0.10) | .63 | .80 | 0.01 (0.10) | .88 | .9 | F<sub>2,2160</sub> = 0.17 | .8 |
| Reaction Time | 102 | 28,898 | 113 | −0.32 (0.10) | .001 | .01<sup>a</sup> | 0.17 (0.10) | .07 | .1 | F<sub>2,21960</sub> = 7.14 | .0008 |
| Fluid Intelligence | 89 | 26,690 | 108 | −0.32 (0.10) | .003 | .01<sup>a</sup> | −0.04 (0.10) | .71 | .8 | F<sub>2,26879</sub> = 4.33 | .01 |
| Digit Span | 71 | 19,799 | 81 | −0.29 (0.12) | .02 | .06 | −0.1 (0.12) | .38 | .5 | F<sub>2,19943</sub> = 3.27 | .04 |
| Symbol Substitution | 62 | 15,127 | 55 | −0.36 (0.13) | .005 | .02<sup>a</sup> | 0.13 (0.13) | .33 | .5 | F<sub>2,15236</sub> = 4.79 | .008 |
| Trail Making A | 52 | 15,538 | 48 | −0.29 (0.14) | .04 | .09 | −0.04 (0.14) | .80 | .8 | F<sub>2,15360</sub> = 5.28 | .08 |
| Trail Making B | 52 | 15,538 | 48 | −0.40 (0.14) | .004 | .02<sup>a</sup> | 0.19 (0.14) | .20 | .3 | F<sub>2,15360</sub> = 5.67 | .003 |

Group differences were assessed using ANOVA followed by post hoc pairwise comparisons. Both uncorrected and FDR-corrected p values are shown.

ANOVA, analysis of variance; BP, breakpoint; CNV, copy number variant; FDR, false discovery rate; NoCNV, no pathogenic CNVs.

<sup>a</sup>p < .05 after FDR correction.
Figure 1. (A) Boxplots showing the effects of 15q11.2 BP1-BP2 copy number variation on Tract-Based Spatial Statistics–derived measures. Group differences between deletion (n = 102), duplication (n = 113), and no pathogenic copy number variant (NoCNV; n = 28,951) carriers were assessed with an analysis of variance followed by post hoc pairwise comparisons. Here, only white matter tracts showing significant group differences after false discovery rate correction for multiple comparisons are shown. Statistics are documented in Table S7 in Supplement 2. *p < .05, **p < .01, ***p < .001. (B) Glass brain representation of the white matter regions defined by the JHU White Matter Atlas (ICBM-DTI-81).
Because FA is the metric more commonly used in DTI studies and the one more widely associated with 15q11.2 BP1-BP2 carrier status here, we focused our mediation analysis only on this measure. As described above, four white matter tracts (ALIC_L, PLIC_L, PTR_R, and Cing_HIP_L) showed FA changes in deletion carriers and three tracts (Cing_CG_R, Cing_HIP_R, and Cing_HIP_L) in duplication carriers when compared with NoCNV carriers. Therefore, the effects of these tracts on fluid intelligence, reaction time, symbol substitution, and trail making B task performance were tested. FA variation in all these tracts was overall significantly associated with cognitive task performance, where increases in FA were associated with better performance (Table 4). Associations between cognitive tests and FA in regions for each CNV carrier status can be seen in Figures S14–S17 in Supplement 1. No significant CNV × FA interactions were observed in cognitive performance.

We found that ALIC_L, PTR_R, and Cing_HIP_L partially mediated cognitive performance in deletion carriers. Decreased FA in PTR_R was found to partially mediate cognitive performance on all four cognitive tasks, accounting for between 2.4% and 6% of the association between carrier status and cognitive performance (Table 4). Increased FA in ALIC_L in deletion carriers was associated with higher scores on reaction time, symbol substitution, and trail making B task performance.

### Table 4. Mediation Analysis Showing the Proportion of the Mediated Effect of FA on the Total Effect of 15q11.2 BP1-BP2 CNV on Reaction Time, Fluid Intelligence, Symbol Substitution, and Trail Making B

| WM Tracts        | Path B | FDR  | Proportion Mediated (CI) | p Value | FDR  | Comparison       |
|------------------|--------|------|--------------------------|---------|------|------------------|
| **Reaction Time** |        |      |                          |         |      |                  |
| ALIC_L           | .03 (.006) | $3.67 \times 10^{-7}$ | $-0.029 (-0.09$ to $-0.01)$ | .004 | .03* | Del vs. NoCNV |
| PLIC_L           | .003 (.006) | $6$ | $-0.003 (-0.02$ to $0.01)$ | .51 | .6  |                  |
| PTR_R            | .03 (.006) | $6.35 \times 10^{-5}$ | $0.024 (0.008$ to $0.07)$ | .003 | .03* |                  |
| Cing_HIP_L       | .02 (.006) | $0.003$ | $-0.022 (-0.07$ to $-0.01)$ | .002 | .03* |                  |
| Cing_CG_R        | .04 (.006) | $1.32 \times 10^{-11}$ | $-0.07 (-0.57$ to $0.26)$ | .07 | .1  | Dup vs. NoCNV |
| Cing_HIP_R       | .03 (.006) | $2.6 \times 10^{-5}$ | $-0.052 (-0.41$ to $0.2)$ | .07 | .1  |                  |
| Cing_HIP_L       | .02 (.006) | $0.003$ | $-0.03 (-0.3$ to $0.16)$ | .09 | .2  |                  |
| **Fluid Intelligence** |        |      |                          |         |      |                  |
| ALIC_L           | .03 (.006) | $4.34 \times 10^{-7}$ | $-0.02 (-0.07$ to $0)$ | .06 | .1  | Del vs. NoCNV |
| PLIC_L           | .02 (.006) | $0.006$ | $-0.012 (-0.05$ to $0)$ | .03 | .9  |                  |
| PTR_R            | .05 (.006) | $2.97 \times 10^{-12}$ | $0.044 (0.015$ to $0.14)$ | .004 | .03* |                  |
| Cing_HIP_L       | .02 (.006) | $0.004$ | $-0.023 (-0.07$ to $-0.01)$ | .007 | .03* |                  |
| Cing_CG_R        | .01 (.006) | $0.06$ | $0.01 (-0.59$ to $0.6)$ | .9 | .9  | Dup vs. NoCNV |
| Cing_HIP_R       | .03 (.006) | $2.75 \times 10^{-5}$ | $0.037 (-1.33$ to $1.66)$ | .9 | .9  |                  |
| Cing_HIP_L       | .02 (.006) | $0.004$ | $-0.03 (-0.88$ to $1.05)$ | .8 | .9  |                  |
| **Symbol Substitution** |        |      |                          |         |      |                  |
| ALIC_L           | .04 (.007) | $3.65 \times 10^{-5}$ | $-0.05 (-0.19$ to $-0.01)$ | .009 | .03* | Del vs. NoCNV |
| PLIC_L           | .009 (.007) | $2$ | $-0.006 (-0.04$ to $0)$ | .2 | .3  |                  |
| PTR_R            | .06 (.007) | $8.94 \times 10^{-13}$ | $0.06 (0.02$ to $0.2)$ | .006 | .03* |                  |
| Cing_HIP_L       | .02 (.008) | $0.001$ | $-0.02 (-0.09$ to $0)$ | .01 | .04* |                  |
| Cing_CG_R        | .05 (.008) | $2.7 \times 10^{-11}$ | $-0.13 (-2.31$ to $1.6)$ | .3 | .4  | Dup vs. NoCNV |
| Cing_HIP_R       | .02 (.008) | $0.04$ | $-0.03 (-0.55$ to $0.35)$ | .3 | .4  |                  |
| Cing_HIP_L       | .02 (.008) | $0.001$ | $-0.05 (-0.75$ to $0.79)$ | .3 | .4  |                  |
| **Trail Making B** |        |      |                          |         |      |                  |
| ALIC_L           | .04 (.008) | $4.11 \times 10^{-7}$ | $-0.06 (-0.25$ to $-0.02)$ | .01 | .04* | Del vs. NoCNV |
| PLIC_L           | .01 (.008) | $1$ | $-0.01 (-0.05$ to $0)$ | .09 | .2  |                  |
| PTR_R            | .05 (.008) | $3.65 \times 10^{-9}$ | $0.04 (0.007$ to $0.15)$ | .02 | .05* |                  |
| Cing_HIP_L       | .01 (.008) | $2$ | $-0.01 (-0.05$ to $0.01)$ | .2 | .3  |                  |
| Cing_CG_R        | .03 (.008) | $0.001$ | $-0.06 (-0.63$ to $0.61)$ | .2 | .3  | Dup vs. NoCNV |
| C_HIP_R          | .003 (.008) | $7$ | $-0.003 (-0.07$ to $0.04)$ | .7 | .8  |                  |
| Cing_HIP_L       | .01 (.008) | $2$ | $-0.01 (-0.28$ to $0.18)$ | .4 | .5  |                  |

Negative proportions indicate opposite signs between the mediator (FA) and the total effect (CNV effect on cognitive measure). The linear regression (Path B) shows the overall effects of white matter on cognition (including all deletion and duplication carriers). Both uncorrected and corrected (FDR) p values are shown.

CI, confidence interval; CNV, copy number variant; Del, deletion; Dup, duplication; FA, fractional anisotropy; FDR, false discovery rate; NoCNV, no pathogenic copy number variant; WM, white matter. See Table 2 for white matter tract abbreviations.

*p < .05 after FDR correction.
We found some divergence between our previous and current results. While deletion carriers showed increased FA in PTR_R and ILF_L in the Icelandic sample, they show reduced FA in the UK Biobank sample, with a significant FA reduction in PTR_R when compared with NoCNV carriers (Figure S5 in Supplement 1). Furthermore, when looking at effect sizes in all tracts (Figures S8–S11 in Supplement 1), an overall pattern of increased FA in deletion carriers in the Icelandic sample can be appreciated (the only exceptions being fornix and bilateral CST), whereas in the UK Biobank, the pattern is more heterogeneous. Divergent results could be explained by important differences between the two studies: the UK Biobank sample is considerably larger in size, increasing statistical power to detect true associations; it also represents a more genetically heterogeneous population of an older age than the Icelandic sample. Moreover, UK Biobank applied DTI acquisition protocols with higher resolution, which could also lead to more robust results.

NDDs have been generally associated with global decreases in FA (33,39,40), which contrasts with the findings of increased FA in 15q11.2 BP1-BP2 deletion carriers. This raises the question of how changes in FA relate to cognitive function and risk for disorder in these carriers. In our neuroimaging sample, deletion carriers performed worse during reaction time, fluid intelligence, symbol substitution, and trail making B tasks, whereas duplication carriers performed at a similar level as NoCNV control subjects in all tasks. The same pattern was observed when extending our analyses to all participants with cognitive data available, where additional effects in pairs matching and digit span tasks were seen in deletion carriers (Table S6 in Supplement 2). This pattern of effects is in line with previous studies, where the 15q11.2 BP1-BP2 deletion was reported as being more damaging than duplication for a variety of cognitive tests (7,16).

Our analyses show that FA in white matter tracts affected by CNV carrier status correlates positively with cognitive performance in reaction time, fluid intelligence, symbol substitution, and trail making B tasks. Mediation analysis revealed that changes in PTR_R partially mediated the effects of deletion in all cognitive tasks, where lower FA in PTR_R in deletion carriers contributed to 2%–6% of the CNV effect across tasks. PTR is known to connect the caudal parts of the thalamus to both the parietal and occipital lobes (41) and has been previously indicated as the strongest white matter predictor for fluid intelligence (42). Conversely, the increased FA seen in ALIC_L and Cing_HIP_L in deletion carriers had the opposite effect on cognition, removing part of the CNV effect on performance. These findings suggest that increased FA in these regions contributes to better cognitive performance in deletion carriers.

A recent study used data gathered through the Enhancing Neuro Imaging Genetics through Meta Analysis (ENIGMA) consortium (43) and UK Biobank to determine the effects of the 15q11.2 BP1-BP2 CNV on cortical and subcortical brain morphology. The study reported reduced brain surface area and thicker cortex in deletion carriers, where the significant differences in cortical thickness were more evident in the frontal, cingulate, and parietal lobes. Furthermore, this study found significant mediation effects of total surface area and cortical thickness on fluid intelligence, with similar proportions as the ones reported in this study (16). Taken together, these
findings suggest that 15q11.2 BP1-BP2 CNV effects on white and gray matter provide partially complementary effects on cognitive ability.

Among the four genes in this region, NIPA1 and CYFIP1 are known to be involved in mechanisms that, when dysregulated, have the potential to alter white matter. NIPA1 interacts with the bone morphogenetic protein (BMP) receptor type II to inhibit BMP signaling, which contributes to axonal growth, guidance, and differentiation (44). Enhanced BMP signaling was found to cause abnormal distal axonal overgrowth at the presynaptic neuromuscular junction in a Drosophila model (45). CYFIP1 is considered a likely contributor to 15q11.2 BP1-BP2-associated phenotypes. Dysregulations in this gene result in alterations in dendritic spine morphology and branching (46,47), CYFIP1 interacts in two distinct complexes (46)—the WAVE regulatory complex, which regulates actin remodeling during neural wiring (48), and the CYFIP1-elf4E complex, which, through interactions with FMRP, regulates translation of FMRP-target messenger RNAs (49). FMRP is the gene product of FMR1, which, when mutated, causes fragile X syndrome, the most common monogenic form of intellectual disability (50).

In our previous study, we hypothesized that CYFIP1 could be a primary contributor to white matter changes in 15q11.2 BP1-BP2 CNV carriers. Previous DTI studies have shown increased FA in patients with fragile X syndrome (51,52), similar to what we observed in 15q11.2 BP1-BP2 deletion carriers, suggesting that these changes could be in part due to disruptions in the CYFIP1-FMRP complex. Recently, we developed a novel Cyfip1-haploinsufficient rat line using CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 to assess the influence of Cyfip1 on white matter (53). Cyfip1 haploinsufficiency led to decreased FA, myelin thinning in the corpus callosum, and aberrant intracellular distribution of myelin basic protein in cultured oligodendrocytes. These findings contrasted with our previous results from the Icelandic sample, showing widespread increased FA in 15q11.2 BP1-BP2 deletion carriers. However, in the UK Biobank sample, reduced FA was found in PTR_R in deletion carriers, which contributed to worse cognitive performance. Decreased FA could indeed result from myelin deficits (54) that could be caused by dysregulations in CYFIP1, which could in turn affect cognition (55,56). Conversely, increased FA in ALIC_L and Cing_HIP_L led to better cognitive performance in deletion carriers, which could be associated with compensatory mechanisms as a response to primary deficits (e.g., in myelination or synapses). It is, however, difficult to speculate at this point, given that the individual or combined influence of the other three genes in this region on white matter is unknown, and disruptions to myelin and/or axons cannot be distinguished with traditional DTI methods.

The effect sizes reported here were overall smaller than the ones in the Icelandic sample. In this study, we compared carriers to thousands of control subjects, which provides a better estimate of the general population mean and therefore a more reliable estimate of effect sizes (57). In the Icelandic sample, carriers were compared with 19 NoCNV control subjects, which may have led to an overestimation of the CNV effect. The 15q11.2 BP1-BP2 deletion has been proposed as a variant of uncertain clinical significance. However, more recent meta-analyses on published case-control studies have classified the deletion as a pathogenic of mild effect size (58). It is also important to note that the recruitment in UK Biobank and Iceland relies on volunteers who put themselves forward to be scanned, which could result in a significant healthy volunteer bias (59).

Different sample characteristics and imaging acquisition protocols could explain some of the variability between our previous and current results. However, it is encouraging that we found concordant results from different samples, increasing our confidence of a CNV effect on white matter, particularly on the cingulum and internal capsule, which harbor important connections of the limbic system.

Conclusions

We provide converging evidence from two independent samples with different genetic and environmental backgrounds supporting the effects of 15q11.2 BP1-BP2 carrier status on white matter microstructure, with larger effects in deletion than duplication carriers. Our results also point toward a dose-dependent effect, showing a linear trend in most tracts, where carriers of no CNVs sit between deletion and duplication carriers. We further show that changes in white matter partially mediate the association between CNV carrier status and cognitive performance. These results add to the evidence of white matter changes as being an intermediate phenotype between genetic risk variants and cognitive or clinical phenotypes.

ACKNOWLEDGMENTS AND DISCLOSURES

This research was conducted using the UK Biobank Resource under Application Number 17044. This research was supported by the Medical Research Council Programme (Grant No. G080050009); a Wellcome Trust Strategic Award ‘DEFINE’ (Grant No. 100202/Z/11/Z) [to JH, LSW, and DEJL]; core support from the Neuroscience and Mental Health Research Institute, Cardiff University; and a Wellcome Trust Clinical Research Training Fellowship (Grant No. 201171/Z/16/Z) [to KMK].

MOU, GBW, HS, and KS are employees of deCODE genetics/Amgen. All other authors report no biomedical financial interests or potential conflicts of interest.

ARTICLE INFORMATION

From the Neuroscience and Mental Health Research Institute (AIS, GK, KMK, MB-S, LSW, JH, DEJL, XC), MRC Centre for Neuropsychiatric Genetics and Genomics; Cardiff University Brain Research Imaging Centre School of Psychology (AIS); Division of Psychological Medicine and Clinical Neurosciences (LSW, JH), School of Medicine; School of Psychology (LSW), Cardiff University, Cardiff, United Kingdom; School for Mental Health and Neuroscience (AIS, DEJL), Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands; deCODE genetics/Amgen (MOU, GBW, HS, KS); and Faculty of Electrical and Computer Engineering (MOU) and Faculty of Medicine (GBW, KS), University of Iceland, Reykjavik, Iceland.

DEJL and XC contributed equally to this work as joint senior authors. Address correspondence to Ana I. Silva, Ph.D., at silvaai@cardiff.ac.uk, or Xavier Caseras, Ph.D., at caserasx@cardiff.ac.uk.

Received Aug 27, 2020; revised and accepted Feb 23, 2021.

Supplementary material cited in this article is available online at https://doi.org/10.1016/j.biopsych.2021.02.989.
15q11.2 CNV Effects on White Matter and Cognition

REFERENCES

1. Kirov G (2015): CNVs in neuropsychiatric disorders. Hum Mol Genet 24:R45–R68.
2. Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, et al. (2017): Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet 49:27–35.
3. Coe BP, Witherspoon K, Rosenfeld JA, van Bon BW, Volto-van Silfhout AT, Bosco P, et al. (2014): Refining analyses of copy number variation identifies specific genes associated with developmental delay. Nat Genet 46:1063–1071.
4. Kochunov P, Coyle TR, Rowland LM, Jahanshad N, Thompson PM, Kelly S, et al. (2017): Association of white matter with core cognitive deficits in patients with schizophrenia. JAMA Psychiatry 74:958–966.
5. Karbasforoushan H, Duffy B, Blackford JJ, Woodward ND (2015): Processing speed impairment in schizophrenia is mediated by white matter integrity. Psychol Med 45:103–120.
6. Takumi T, Tamada K (2018): CNV biology in neurodevelopmental disorders. Curr Opin Neurolol 48:183–192.
7. Stefansson H, Meyer-Lindenberg A, Steinberg S, Magnusdottir B, et al. (2009): Large-scale candidate gene analyses of schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet 41:65–72.
8. Crawford K, Bracher-Smith M, Owen D, Kendall KM, Rees E, Pardiñas AF, et al. (2019): Medical consequences of pathogenic CNVs in adults: Analysis of the UK Biobank. J Med Genet 56:131–138.
9. Butler MG (2017): Clinical and genetic aspects of the 15q11.2 BP1-BP2 region with cortical and subcortical morphology and cognition. JAMA Psychiatry 74:958–966.
10. Williams SG, Nakae A, Guo H, Frain S, Tenin G, Liakhoivtsia A, et al. (2020): Association of congenital cardiovascular malformation and neuropsychiatric phenotypes with 15q11.2 (BP1–BP2) deletion in the UK Biobank. Eur J Hum Genet 28:1265–1273.
11. Gosciejewski BJ, Bick AG, Ito K, Homsy J, Rodriguez-Murillo L, Fromer M, et al. (2014): Increased frequency of de novo copy number variants in congenital heart disease by integrative analysis of single nucleotide polymorphism array and exome sequence data. Circ Res 115:884–896.
12. Bumsíde PD, Fasion R, Mikhail FM, Carroll AJ, Robin NH, Youngs EL, et al. (2011): Microdeletion/microduplication of proximal 15q11.2 between BP1 and BP2: A susceptibility region for neurological dysfunction including developmental and language delay. Hum Genet 130:517–528.
13. van der Zwaag B, Staal WG, Hochstenbach R, Poot M, Spijerenburg HA, de Jonge MV, et al. (2010): A co-segregating microduplication of chromosome 15q11.2 pinpoints two risk genes for autism spectrum disorder. Am J Hum Genet 87:960–966.
14. Writing Committee for the ENIGMA-CNVA Working Group, van der Meer D, Senderby IE, Kaufmann T, Walters GB, Abdelaioua A, et al. (2020): Association of copy number variation of the 15q11.2 BP1–BP2 region with cortical and subcortical morphology and cognition. JAMA Psychiatry 77:420–430.
15. Ulfarsson MO, Walters GB, Gustafsson O, Steinberg S, Silva A, Doyle OM, et al. (2017): 15q11.2 CNV affects cognitive, structural and functional correlates of dyslexia and dyscalculia. Transl Psychiatry 7:1109.
16. Chai JH, Lackie DP, Grealy JM, Knoll JHM, Ohta T, Dunai J, et al. (2003): Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons. Am J Hum Genet 73:898–925.
17. Rainier S, Chai JH, Tokarz D, Nicholls RD, Fink JK (2003): NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6). Am J Hum Genet 73:967–971.
18. Xie H, Zhang Y, Zhang P, Wang J, Wu Y, Wu X, et al. (2014): Functional study of NIPA2 mutations identified from the patients with childhood absence epilepsy. PLoS One 9:e109749.
19. Toma C, Tonrico B, Hervás A, Valdés-Mas R, Trístán-Noguero A, Padillo V, et al. (2014): Exome sequencing in multiplex autism families suggests a major role for heterogeneous truncating mutations. Mol Psychiatry 19:784–790.
20. Tam GWC, van de Lagemaat LN, Redon R, Strathekke KE, Croning MDR, Malloy MP, et al. (2010): Confirmed rare copy number variants implicate novel genes in schizophrenia. Biochim Biophys Acta 38:445–451.
21. Rafi SK, Butler MG (2020): The 15q11.2 BP1–BP2 microdeletion (Bursmide-Butler) syndrome: In silico analyses of the four coding genes reveal functional associations with neurodevelopmental phenotypes. Int J Mol Sci 21:3296.
22. Silva AI, Ulfarson MO, Stefansson H, Gustafsson O, Walters GB, Linden DEJ, et al. (2019): Reciprocal white matter changes associated with copy number variation at 15q11.2 BP1–BP2: A diffusion tensor imaging study. Biol Psychiatry 85:563–572.
23. Helgason A, Nicholson G, Stefánsson K, Donnelly P (2003): A reassessment of genetic diversity in Icelanders: Strong evidence from multiple loci for relative homogeneity caused by genetic drift. Ann Hum Genet 67:281–297.
24. Zeggini E (2014): Using genetically isolated populations to understand the genomic basis of disease. Genome Med 6:83.
25. Austin MA, Harding S, McElroy C (2003): Genebanks: A comparison of eight proposed international genetic databases. Commun Genet 6:37–45.
26. Legge SE, Jones HJ, Kendall KM, Pardiñas AF, Menzies G, Bracher-Smith M, et al. (2019): Association of genetic liability to psychotic experiences with neuropsychiatric disorders and traits. JAMA Psychiatry 76:1256–1265.
27. Kendall KM, Rees E, Escott-Price V, Eskin E, Thomas R, Hewitt J, et al. (2017): Cognitive performance among carriers of pathogenic copy number variants: Analysis of 152,000 UK Biobank subjects. Biol Psychiatry 82:103–110.
28. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SFA, et al. (2007): PennCNV: An integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 17:1665–1674.
29. Ottwald P, Gambin T, Szafrański P, Li J, Amato S, Divon MY, et al. (2013): NAHR-mediated copy-number variants in a clinical population: Mechanistic insights into both genomic disorders and Mendelian traits. Genome Res 23:1395–1409.
30. Mori S, Wakanke S, van Zijl PCM, Naga-Poetscher LM (2005): MRI Atlas of Human White Matter. Amsterdam: Elsevier.
31. Koshiyama D, Fukunaga M, Okada N, Morita K, Nemoto K, Usui K, et al. (2020): White matter microstructural alterations across four major psychiatric disorders: Mega-analysis study in 2937 individuals. Mol Psychiatry 25:883–895.
32. Benjamini Y, Hochberg Y (1995): Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 57:289–300.
33. Jones DK, Christiansen KF, Chapman RJ, Aggleton JP (2013): Distinct point hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes: In silico analyses of the four coding genes reveal functional associations with neurodevelopmental phenotypes. Int J Mol Sci 16:4068.
39. Fitzsimmons J, Kubicki M, Shenton ME (2013): Review of functional and anatomical brain connectivity findings in schizophrenia. Curr Opin Psychiatry 26:172–187.
40. Rane P, Cochran D, Hodge SM, Haselgrove C, Kennedy DN, Frazier JA (2015): Connectivity in autism: A review of MRI connectivity studies. Harv Rev Psychiatry 23:223–244.
41. George K, Das MJ (2020): Neuroanatomy, Thalamocortical Radiations. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing. Available at: http://www.ncbi.nlm.nih.gov/books/NBK546699/. Accessed March 22, 2020.
42. Kievit RA, Fuhrmann D, Borgeest GS, Simpson-Kent IL, Henson RNA (2018): The neural determinants of age-related changes in fluid intelligence: A pre-registered, longitudinal analysis in UK Biobank. Wellcome Open Res 3:38.
43. Thompson PM, Stein JL, Medland SE, Hbar DP, Vasquez AA, Renteria ME, et al. (2014): The ENIGMA Consortium: Large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav 8:153–182.
44. Tsang HTH, Edwards TL, Wang X, Connell JW, Davies RJ, Durrington HJ, et al. (2009): The hereditary spastic paraplegia proteins NIPA1, spastin and spartin are inhibitors of mammalian BMP signaling. Hum Mol Genet 18:3805–3821.
45. Wang X, Shaw WR, Tsang HTH, Reid E, O’Kane CJ (2007): Drosophila spichthyin inhibits BMP signaling and regulates synaptic growth and axonal microtubules. Nat Neurosci 10:177–185.
46. De Rubies S, Pascueto E, Li KW, Fernández E, Di Marino D, Buzzi A, et al. (2013): CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation. Neuron 79:1169–1182.
47. Pathania M, Davenport EC, Muir J, Sheehan DF, López-Doménech G, Kittler JT (2014): The autism and schizophrenia associated gene CYFIP1 is critical for the maintenance of dendritic complexity and the stabilization of mature spines. Transl Psychiatry 4:e374.
48. Chen Z, Borek D, Padrick SB, Gomez TS, Metlazel G, Ismail AM, et al. (2010): Structure and control of the actin regulatory WAVE complex. Nature 468:533–538.
49. Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zafra F, De Rubies S, et al. (2008): The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 134:1042–1054.
50. Lozano R, Rosero CA, Hagerman RJ (2014): Fragile X spectrum disorders. Intractable Rare Dis Res 3:134–146.
51. Hall SS, Dougherty RF, Reiss AL (2016): Profiles of aberrant white matter microstructure in fragile X syndrome. Neuroimage Clin 11:133–138.
52. Green T, Barnea-Goraly N, Raman M, Hall SS, Lightbody AA, Bruno JL, et al. (2015): Specific effect of the fragile-X mental retardation-1 gene (FMR1) on white matter microstructure. Br J Psychiatry 207:143–148.
53. Silva AI, Haddon JE, Syed YA, Trent S, Lin T-CE, Patel Y, et al. (2019): Cyfip1 haploinsufficient rats show white matter changes, myelin thinning, abnormal oligodendrocytes and behavioural inflexibility. Nat Commun 10:3455.
54. Alba-Ferrara LM, de Erausquin GA (2013): What does anisotropy measure? Insights from increased and decreased anisotropy in selective fiber tracts in schizophrenia. Front Integr Neurosci 7:9.
55. Fields RD (2008): White matter in learning, cognition and psychiatric disorders. Trends Neurosci 31:361–370.
56. Fields RD (2015): A new mechanism of nervous system plasticity: Activity-dependent myelination. Nat Rev Neurosci 16:756–767.
57. Ferguson CJ (2016): An effect size primer: A guide for clinicians and researchers. In: Kazdin AE, editor. Methodological Issues and Strategies in Clinical Research. Washington, DC: American Psychological Association, 301–310.
58. Jonch AE, Douard E, Moreau C, Van Dijck A, Passeggeri M, Kooy F, et al. (2019): Estimating the effect size of the 15q11.2 BP1–BP2 deletion and its contribution to neurodevelopmental symptoms: Recommendations for practice. J Med Genet 56:701–710.
59. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. (2017): Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol 186:1026–1034.